Can a patient with a history of macular degeneration safely take Viagra (sildenafil)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can You Take Viagra with History of Macular Degeneration?

Yes, patients with a history of macular degeneration can generally take Viagra (sildenafil), though they should be counseled about rare visual side effects and monitored appropriately. The FDA label does not list macular degeneration as a contraindication, and available evidence suggests no significant worsening of AMD with sildenafil use 1.

Key Safety Considerations

Visual Side Effects to Discuss

The primary concern with sildenafil relates to its inhibition of phosphodiesterase type 6 (PDE6) in the retina, which can cause:

  • Temporary blue-green color discrimination difficulties
  • Bluish tinge to vision
  • Difficulty seeing in dim light
  • Increased light sensitivity 2

These effects are typically mild, temporary, and dose-related 2.

Serious but Rare Visual Complications

Patients should be counseled to stop all PDE5 inhibitors and seek immediate medical attention if they experience sudden vision loss in one or both eyes 1. This may indicate:

  • Non-arteritic anterior ischemic optic neuropathy (NAION): Reported rarely in post-marketing surveillance with temporal association to PDE5 inhibitor use 1
  • Increased NAION risk in patients with prior NAION in one eye: These patients should be specifically counseled about potential risks of vasodilators like sildenafil 1

However, it's important to note that causality has not been definitively established—these events may relate to underlying vascular risk factors rather than the medication itself 1.

Evidence Regarding AMD Specifically

No Increased AMD Risk or Progression

The most recent and highest-quality evidence shows:

  • A 2024 UK retrospective cohort study of 31,575 men found no significant association between sildenafil use and AMD incidence (adjusted HR 0.99,95% CI 0.84-1.16) over approximately 3 years of follow-up 3
  • A 2002 randomized controlled trial found no acute visual effects or exacerbation of preexisting visual impairment in men with early-stage AMD taking a single 100mg dose 4
  • A 2005 study showed no significant changes in foveolar choroidal circulation in AMD patients after sildenafil administration 5

Theoretical Benefits Remain Unproven

While some small studies have suggested potential benefits of sildenafil for AMD through increased choroidal perfusion and PDE6 inhibition 6, 7, these findings are not sufficiently robust to recommend sildenafil as AMD treatment, and the 2024 cohort study found no protective effect 3.

Absolute Contraindications (Unrelated to AMD)

Sildenafil is absolutely contraindicated in patients taking nitrates in any form (nitroglycerin, isosorbide dinitrate/mononitrate, recreational "poppers") due to risk of severe, potentially fatal hypotension 2, 8, 1.

Suggested safe intervals after last sildenafil dose before nitrate administration in emergencies:

  • Sildenafil: 24 hours
  • Tadalafil: 48 hours 8

Practical Prescribing Approach

Initial Assessment

  • Verify no concurrent nitrate use
  • Assess cardiovascular fitness for sexual activity 9, 8, 10
  • Screen for history of NAION in either eye
  • Document baseline visual function if AMD is present

Dosing Strategy

  • Start with 50mg, taken 1 hour before sexual activity 2
  • Adjust to 25mg if side effects occur, or 100mg if inadequate response 2
  • Sexual stimulation is required for efficacy 2

Patient Counseling for AMD Patients

  • Explain that AMD itself is not a contraindication
  • Warn about temporary color vision changes (common, benign)
  • Emphasize immediate medical attention for sudden vision loss
  • Discuss increased NAION risk if prior episode in fellow eye
  • Schedule periodic follow-up to assess efficacy, side effects, and any health status changes 8

Special Populations Requiring Dose Adjustment

  • Age >65 years: Start with 25mg 1
  • Severe hepatic/renal impairment: Start with 25mg or avoid 9
  • Concurrent alpha-blocker therapy: Ensure stable on alpha-blocker first, then start sildenafil at lowest dose 9, 8, 1
  • Protease inhibitor use: May limit to 25mg per 48 hours 1

Common Pitfalls to Avoid

  1. Failing to screen for nitrate use: This includes asking about recreational drug use ("poppers")
  2. Not educating about need for sexual stimulation: Accounts for many treatment "failures" 8
  3. Inadequate trial before declaring failure: Patients may need multiple attempts with proper technique 8
  4. Taking with large, high-fat meals: May delay onset of action 1
  5. Overlooking drug interactions: Particularly with alpha-blockers, protease inhibitors, and other antihypertensives 9, 1

2, 9, 8, 1, 3, 4, 5

References

Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2003

Research

Sildenafil in ophthalmology: An update.

Survey of ophthalmology, 2022

Research

Treatment of Macular Degeneration with Sildenafil: Results of a Two-Year Trial.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2018

Guideline

erectile dysfunction: aua guideline.

The Journal of urology, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.